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Summary: Successful deployment of machine learning algorithms in healthcare requires careful assessments of their
performance and safety. To date, the FDA approves locked algorithms prior to marketing and requires future updates to
undergo separate premarket reviews. However, this negates a key feature of machine learning–the ability to learn from a
growing dataset and improve over time. This paper frames the design of an approval policy, which we refer to as an automatic
algorithmic change protocol (aACP), as an online hypothesis testing problem. As this process has obvious analogy with
noninferiority testing of new drugs, we investigate how repeated testing and adoption of modifications might lead to gradual
deterioration in prediction accuracy, also known as “biocreep” in the drug development literature. We consider simple policies
that one might consider but do not necessarily offer any error-rate guarantees, as well as policies that do provide error-rate
control. For the latter, we define two online error-rates appropriate for this context: Bad Approval Count (BAC) and Bad
Approval and Benchmark Ratios (BABR). We control these rates in the simple setting of a constant population and data source
using policies aACP-BAC and aACP-BABR, which combine alpha-investing, group-sequential, and gate-keeping methods. In
simulation studies, bio-creep regularly occurred when using policies with no error-rate guarantees, whereas aACP-BAC and
-BABR controlled the rate of bio-creep without substantially impacting our ability to approve beneficial modifications.
Key words: AI/ML-based SaMD; Alpha-investing; Gate-keeping; Group-sequential; Online hypothesis testing.
Due to the rapid development of artificial intelligence (AI)
and machine learning (ML), the use of AI/ML-based algo-
rithms has expanded in the medical field. As such, an increas-
ing number of AI/ML-based Software as a Medical Device
(SaMD) are seeking approval from the Center of Diagnostics
and Radiologic Health (CDRH) at the US Food and Drug
Administration (FDA). ML algorithms are attractive for their
ability to improve over time by training over a growing body
of data. Thus, rather than using a locked algorithm trained on
a limited dataset, developers might like to train it further on
a much more representative sample of the patient population
that can only be obtained after deployment. To collect input
on this regulatory problem, the FDA recently outlined a
proposed regulatory framework for modifications to AI/ML-
based SaMDs in a discussion paper (FDA, 2019).
Regulating evolving algorithms presents new challenges
because the CDRH has historically only approved “locked”
algorithms, i.e. algorithms that do not change after they are
approved. This is a new regulatory problem because updating
traditional medical devices and drugs is often logistically
difficult whereas updating software is both fast and easy.
FDA (2019) proposes companies stipulate SaMD Pre-
specifications (SPS) and an Algorithm Change Protocol
(ACP). When listing the anticipated modifications in the SPS,
it behooves the company to cast as wide a net as possible
within FDA-imposed constraints. The ACP specifies how the
company will ensure that their modifications are acceptable
for deployment. Once the FDA approves the SPS and ACP,
the company follows these pre-specified procedures to deploy
changes without further intervention. As such, we refer to
the ACP in this paper as an “automatic ACP” (aACP). The
aACP is the FDA’s primary tool for ensuring safety and
efficacy of the modifications. However, specific aACP designs
or requirements are noticeably absent from FDA (2019). This
paper aims to address this gap.
A manufacturer has two potential motivations for changing
an AI/ML-based SaMD: to advance public health and to
increase their financial wealth. Modifications that improve
performance and usability are encouraged. On the other hand,
changes that do not and are deployed only for the sake
of change itself have been used in the past to advance a
manufacturer’s financial interest and are contrary to public
interest. Historically, such modifications have been used to
1) decrease competition because it is difficult for competitors
to compare against an ever-changing benchmark; 2) file for
a patent extension and keep prices artificially high; and 3)
increase sales for a supposedly new and improved product
(Gupta et al., 2010; Hitchings et al., 2012; Gottlieb, 2019).
To prevent this type of behavior with drugs and biologics,
the FDA regulates modifications through various types of
bridging studies (International Conference on Harmonisation
(1998)). Likewise, an aACP should only grant approval to
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2modifications to AI/ML-based SaMD after ensuring safety
and efficacy.
This paper provides a framework for designing and evaluat-
ing an aACP, considers a variety of aACP designs, and inves-
tigates their operating characteristics. We assume the manu-
facturer is allowed to propose arbitrary (and possibly delete-
rious) modifications, which include changes to model param-
eters, structure, and input features. For this manuscript, we
focus on the setting of a constant population and data source,
rather than more complicated settings with significant time
trends. Throughout, we evaluate modifications solely in terms
of their operating characteristics. Thus, the aACPs treat sim-
ple models and complex black-box estimators, such as neural
networks and boosted gradient trees, the same. This parallels
the drug approval process, which primarily evaluates drugs on
their efficacy and safety with respect to some endpoints, even
if the biological mechanism is not completely understood.
To our knowledge, there is no prior work that directly
addresses the problem of regulating modifications to AI/ML-
based SaMD, though many have studied related problems.
In online hypothesis testing, alpha-investing procedures are
used to control the online false discovery rate (FDR) (Foster
and Stine, 2008; Javanmard and Montanari, 2015; Ramdas
et al., 2017, 2018; Zrnic et al., 2018), which is important for
companies that test many hypotheses over a long period of
time (Tang et al. (2010)). We will consider aACPs that use
alpha-investing to control online error rates; However, we will
need to significantly adapt these ideas for use in our context.
In addition, differential privacy methods (Blum and Hardt,
2015; Dwork et al., 2015) have been used to tackle the problem
of ranking model submissions to a ML competition, where
the submissions are evaluated using the same test data and
models are submitted in a sequential and adaptive manner.
Though that problem is related, those approaches cannot
evaluate modifications that add previously-unmeasured co-
variates. Finally, online learning methods are a major mo-
tivation for studying this regulatory problem and can be
used to automatically update the model (Shalev-Shwartz,
2012). However, rather than designing bespoke aACPs for
online learning methods, we will consider approval policies
for arbitrary modifications as a first step.
This paper evaluates the rates at which different policies
make bad approvals as well as their rates of approving bene-
ficial modifications. Due to the analogy between this problem
and noninferiority testing of new drugs, we investigate how
repeated testing of proposed modifications might lead to
gradual deterioration in model performance, also known as
“bio-creep” (Fleming, 2008). We compare simple aACPs that
one might consider, but do not necessarily have error-rate
guarantees, to policies that do provide error rate control.
For the latter, we define two online error rates appropriate
for this context—the expected Bad Approval Count (BAC)
and Bad Approval and Benchmark Ratios (BABR)—and
control them using policies aACP-BAC and aACP-BABR,
respectively. In simulation studies, bio-creep frequently oc-
curred when using the simple aACPs. By using aACP-BAC
or -BABR instead, we significantly reduce the risk of bio-
creep without substantially reducing our power at detecting
beneficial modifications. Based on these findings, we conclude
that 1) bio-creep is a major concern when designing an aACP
and 2) there are promising solutions for mitigating it without
large sacrifices in power.
1. Motivating examples
We present examples of actual AI/ML-based medical devices
and discuss possible modifications that manufacturers might
consider. The examples are ordered by increasing regulatory
complexity and risk. Throughout, we only discuss regulating
modifications to the software and assume the intended use of
the device remains constant.
1.1 Blood tests using computer vision
Sight Diagnostics has developed a device that collects and im-
ages blood samples to estimate complete blood count (CBC)
parameters. They are evaluating the device in a clinical trial
(ClinicalTrials.gov ID NCT03595501) where the endpoints
are the estimated linear regression parameters (slope and
intercept) between their CBC parameter estimates and gold
standard.
The FDA requires locking the entire procedure, which
includes blood collection, imaging, and the ML algorithm,
prior to marketing. Nonetheless, the company might want
to improve the accuracy of their test after obtaining regu-
latory approval. For instance, they can train more complex
models that capture nonlinearities and interactions (between
covariates and/or outcomes) or use a different FDA-approved
device to image the blood sample. All these changes have
the potential to improve prediction accuracy, though it is not
guaranteed.
To regulate such modifications, we will need to define
acceptable changes to endpoint values. This is not straight-
forward when multiple endpoints are involved: Do all end-
points have to improve? What if the model has near-perfect
performance with respect to some endpoints and room for
improvement for others? To tackle these questions, we must
run both superiority and non-inferiority (NI) tests. Moreover,
introducing NI tests prompts even more questions, such as
how to choose an appropriate NI margin.
1.2 Detecting large vessel occlusion from CT angiogram
images of the brain
ContaCT is a SaMD that identifies whether CT angiogram
images of the brain contain a suspected large vessel occlusion.
If so, it notifies a medical specialist to intervene. The manu-
facturer evaluated ContaCT using images analyzed by neuro-
radiologists. The primary endpoints were estimated sensitiv-
ity and specificity. The secondary endpoint was the difference
in notification time between ContaCT and standard-of-care.
ContaCT achieved 87% sensitivity and 89% specificity and
significantly shortened notification time.
Having obtained FDA approval (FDA, 2018), the company
might want to improve ContaCT by, say, training on more
images, extracting a different set of image features, or uti-
lizing clinical covariates from electronic health records. This
last modification type requires special consideration since
the distribution of clinical covariates and their missingness
distribution are susceptible to time trends.
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1.3 Blood test for cancer risk prediction
GRAIL is designing a blood test that sequences cell-free
nucleic acids (cfNAs) circulating in the blood to detect cancer
early. They are currently evaluating this test in an observa-
tional study (ClinicalTrials.gov ID NCT02889978) where the
gold standard is a cancer diagnosis from the doctor within
30 months. For time-varying outcomes, one may consider
evaluating performance using time-dependent endpoints, such
as those in Heagerty and Zheng (2005).
After the blood test is approved, GRAIL might still want
to change their prediction algorithm. For example, they could
collect additional omics measurements, sequence the cfNAs
at a different depth (e.g. lower to decrease costs, higher to
improve accuracy), or train the model on more data. Regu-
lating modifications to this blood test is particularly difficult
because the gold standard might not be observable in all
patients, its definition can vary between doctors, and it cannot
be measured instantaneously. In fact, the gold standard might
not be measurable at all because test results will likely affect
patient and doctor behavior.
2. Problem Setup
In this section, we provide a general framework and abstrac-
tions to understand the approval process for modifications to
AI/ML-based SaMD. We begin with reviewing the approval
process for a single AI/ML-based SaMD since it forms the
basis of our understanding and is a prerequisite to getting
modifications approved.
2.1 AI/ML-based SaMD
Formally, the FDA defines SaMD as software intended to
be used for one or more medical purposes without being
part of a hardware medical device. An AI/ML-system is
software that learns to perform a specific task by tracking
performance measures. The FDA approves a SaMD for a
specific indication, which describes the population, disease,
and intended use. We only focus on SaMDs intended to be
inform and are approved based on predictive accuracy, not
those that prescribe treatment and are evaluated based on
patient outcomes.
Predictive accuracy is typically characterized by multiple
endpoints, or co-primary endpoints (Offen et al., 2007; FDA,
2017). The most common endpoints for binary classifiers are
sensitivity and specificity because they tend to be indepen-
dent of disease prevalence, which can vary across subpopula-
tions (Pepe, 2003). Additionally, we can evaluate endpoints
over different subgroups to guarantee a minimum level of
accuracy for each one.
We now define a model developer (the manufacturer) in
mathematical terms. Let X be the support of the targeted
patient population, where a patient is represented by their
covariate measurements. Let Y be output range (possibly mul-
tivariate). Let Q be a family of prediction models f ∶ X ↦ Y.
Each model f defines the entire pipeline for calculating the
SaMD output, including feature extraction, pre-processing
steps, and how missing data is handled. The model developer
is a functional g that maps the training data (XT , YT ) ∈Xn×Yn to a function inQ. Let P be the family of distributions
for X ×Y . The performance of a model f on population P ∈ P
is quantified by the K-dimensional endpoint m ∶ Q×P ↦ RK .
For each endpoint mk, we assume that a larger value indicates
better performance.
2.2 Modifications to AI/ML-based SaMD
The proposed workflow in FDA (2019) for modifying an
AI/ML-based SaMD iterates between three stages. First,
the manufacturer proposes a modification by training on
monitoring and/or external data and adds this to a pool
of proposed modifications. Second, the aACP evaluates each
candidate modification and grants approval to those satisfying
some criteria. The most recently approved version is then
recommended to doctors and patients. Finally, monitoring
data is collected, which can be used to evaluate and train
future models.
Within this workflow, the model developer acts in a sequen-
tial and possibly adaptive manner. For simplicity, consider a
fixed grid of time points t = 1,2, .... Since we allow arbitrary
modifications, we treat each modification as an entirely sepa-
rate model. At each time point, the model developer proposes
a new model and adds it to the pool of candidates. (For
example, they may submit a new model trained on monitoring
data obtained at the end of each month.) Let filtration Ft be
the sigma algebra representing the information up to time t,
which includes observed monitoring data, proposed models,
and aACP outputs up to time t. The model developer is a
sequence of functionals {gt ∶ t = 1,2, ...}, where gt is a Ft-
measurable functional mapping to Q. Let fˆt be the realized
model proposal at time t. In addition, suppose that each
proposed model fˆt has a maximum wait time ∆t that specifies
how long the manufacturer will wait for approval of this
model, i.e. the model is no longer considered for approval
after time t +∆t.
Time trends are likely to occur in long-running processes, as
found in long-running clinical trials and non-inferiority trials
(Altman and Royston, 1988; Fleming, 2008). This includes
changes to any component of the joint distribution between
the patient population and the outcome, such as the marginal
distributions of the covariates, their correlation structure,
their prognostic values, and the prevalence of the condition.
As such, let the joint distribution at time t of patients Xt and
outcomes Yt be denoted Pt. The value of endpointm for model
f at time t is then m(f,Pt). More generally, we might charac-
terize a model at time t by the average endpoint value over the
previous D time points, as evaluated by m(f,Pt∶t+D−1) where
Pt∶t′ indicates a uniform mixture of Pt, ...,Pt′ . Here D acts as
a smoothing parameter; Larger D increases the smoothness
of endpoint values.
Finally, this paper assumes that monitoring data collected
at time t are representative of the current population Pt.
Of course, satisfying this criteria is itself a complex issue.
We will not discuss the challenges here and instead refer
the reader to Pepe (2003) for more details, such as selecting
an appropriate sampling scheme, measuring positive versus
negative examples, and obtaining gold standard versus noisy
labels.
2.2.1 Defining acceptable modifications. A fundamental
building block for designing an aACP is defining when a
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Figure 1. Example of an acceptability graph for binary
classifiers evaluated on sensitivity and specificity. Given a
reference model (triangle) and NI margin , a candidate model
is acceptable if one endpoint is non-inferior and the other is
superior compared to the reference model. The NI margin can
be chosen to encourage approval of updates to a better ROC
curve. Models in the shaded blue area are acceptable updates
to the reference model. Model 3 is not acceptable since it is
on a strictly inferior ROC curve. Model 1 and 2 are likely on
better ROC curves, but 1 is not within the NI margin and is
therefore not acceptable either.
modification is acceptable to a reference model. Our solution
is to represent which modifications are acceptable using a
directed graph between models in Q. If there is a directed
edge from model f to model f ′, then it is acceptable to update
f to f ′. This “acceptability graph” is parameterized by a pre-
defined vector of non-inferiority margins  ∈ RK+ . An update
from f to f ′ is acceptable if it demonstrates non-inferiority
with respect to all endpoints and superiority in at least one
(Bloch et al., 2001, 2007). So for a binary classifier where the
endpoints are sensitivity and specificity, one may select the
NI margins to encourage modifications that shift the model
to a better ROC curve (Figure 1). An acceptability graph is
formally defined below:
Definition 1: For a fixed evaluation window D ∈ Z+ and
NI margin  ∈ RK+ , the acceptability graph at time t overQ contains the edge from f to f ′ if mk(f,Pt∶t+D−1) − k ≤
mk(f ′,Pt∶t+D−1) for all k = 1, ...,K and there is some k =
1, ...,K such that mk(f ′,Pt∶t+D−1) > mk(f,Pt∶t+D−1). The
existence of this edge is denoted f →,D,t f ′ and f ↛,D,t f ′
otherwise.
In this paper, we assumeD is fixed and use the notation f →,t
f ′. For simplicity, Definition 1 uses the same NI margin across
all models. In practice, it may be useful to let the margin
depend on the reference model or the previously established
limits of its predictive accuracy.
We obtain different graphs for different choices of . For
instance,  = 0 means that a model is only acceptable if it
is superior with respect to all endpoints, though this can
be overly strict in some scenarios. Setting  ≠ 0 is useful
for approving modifications that maintain the value of some
endpoints or have very small improvements with respect to
some endpoints.
Finally, we define hypothesis tests based on the accept-
Pool of candidate 
algorithmŝfj j = 1,...,t
ApprovalŝAj j = 1,...,t − 1
Automatic Algorithm 
Change Protocol 
(aACP)
̂At:  Most recently approval up to time t
Monitoring data 
up to time t
Figure 2. An automatic Algorithm Change Protocol
(aACP) outputs the index of the most recently approved
model Aˆt at each time t. To do so, it evaluates the pool
of candidate models against the pool of previously approved
models using monitoring data collected up to that time.
ability graph. In an -acceptability test, we test the null
hypothesis is that a model f ′ is not an -acceptable update
to model f at time t, i.e. H0 ∶ f ↛,t f ′ . A superiority test is
simply an -acceptability test where  = 0.
3. An online hypothesis testing framework
At each time point, we suppose an aACP evaluates which
candidates to approve by running a battery of hypothesis
tests. As such, we frame an aACP as an online hypothesis
testing procedure. In contrast to one-time hypothesis tests,
online hypothesis testing procedures aim to control the error
rate over a sequence of tests. Accounting for the multiplicity
of hypotheses is important since new modifications to an
AI/ML-based SaMD can be proposed more easily and fre-
quently compared to the drug development setting.
Each aACP specifies a sequence of approval functions At
for times t = 1,2, ... (Figure 2), where At is a F˜t-measurable
function that outputs the index of the most recently approved
model at time t (some value in {0, ..., t−1}). Filtration F˜t is the
sigma-algebra for monitoring data up to time t and proposed
models and aACP outputs up to time t − 1. The index of the
latest approved model at time t is denoted Aˆt. A model was
approved at time t if Aˆt ≠ Aˆt−1. Assuming companies are not
interested in approving older models, we require Aˆt ≥ Aˆt−1.
Different approval functions lead to different aACPs. For
example, the following are two simple aACPs that one may
plausibly consider but do not provide error-rate guarantees.
aACP-Baseline approves any modification that demon-
strates -acceptability to the initially approved model at a
fixed level α. This can be useful when the initial model has
high predictive accuracy. The manufacturer may also argue
this is reasonable policy because the current laws only require
a model to perform better than placebo, i.e. the standard of
care without utilizing AI/ML-based SaMDs.
aACP-Reset approves any modification that demonstrates
-acceptability to the currently approved model at some fixed
level α. As opposed to aACP-Baseline, this policy encourages
the model to improve over time.
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4. Online error rates for aACPs
We define two online Type I error rates that an aACP might
try to control and describe aACPs that uniformly control the
error rates over time. Manufacturers and regulators should
select the error rate definition and aACP most suitable for
their purposes. These aACPs achieve error rate control as
long as their individual hypothesis tests are controlled at
their nominal levels. We achieve this by testing on only
prospectively-collected monitoring data.
For both definitions, the error rate at time T is evaluated
over a window of width W , i.e. time points 1 ∨ (T −W ) to
T . The hyperparameter W must be pre-specified and specifies
different trade-offs between error control and speed: W = ∞
requires the strongest error rate control, but is overly strict in
most cases, and W = 1 requires the weakest error control, but
can lead to bad long-running behavior. The desired trade-off
is typically in between these extremes.
4.1 Bad approval count
We define a bad approval as one where the modification is
unacceptable with regards to any of the previously approved
models. The first error rate is defined as the expected Bad
Approval Count (BAC) within the current window of width
W :
Definition 2: The expected bad approval count within
the W -window at time T is
BACW (T ) = E ⎡⎢⎢⎢⎢⎣
T∑
t=1∨(T−W )1{∃t′ = 1, ..., t − 1 s.t. fˆAˆt′ ↛,t fˆAˆt}
⎤⎥⎥⎥⎥⎦ .
This error rate captures two important ways errors can accu-
mulate over time: bio-creep and the multiplicity of hypothe-
ses. We discuss these two issues below.
When a sequence of NI trials is performed and the reference
in each trial is the latest model that demonstrated NI, the
performance of the approved models will gradually degrade
over time; This phenomenon has been called bio-creep in pre-
vious work (Fleming, 2008). Bio-creep can also happen in our
setting: Even if each approved model demonstrates superiority
with respect to some endpoints and NI with respect to others,
repeated applications of -acceptability tests can still lead
to approval of strictly inferior models. The risk of bio-creep
is particularly pronounced because the model developer can
perform unblinded adaptations. To protect against bio-creep,
Definition 2 counts it as a type of bad approval.
Second, when a long sequence of hypothesis tests is per-
formed, the probability of a false rejection is inflated due
to the multiplicity of hypotheses. Definition 2 accounts for
multiplicity by summing the probabilities of bad approvals
across the window. It is an upper bound for the probability of
making any bad approval within the window, which is similar
to the definition of family-wise error rate (FWER). In fact, we
use the connection between FWER and BAC in the following
section to design an aACP that controls this error rate.
4.1.1 aACP to control bad approval counts. We now
present aACP-BAC, which uniformly controls BACW (⋅). An
aACP is defined by its skeletal structure, which specifies the
̂A2 = 0 ̂A3 = 1 ̂A4 = 1
H 0̂
f0↛ϵ ̂f1
H 0̂
f0↛ϵ ̂f2
̂A1 = 0
Time 1                        2                          3                          4       
H 0̂
f1↛ϵ ̂f3 ̂f0↛ϵ ̂f3OR
Figure 3. At each time point, this simple aACP launches a
single group sequential test (GST) comparing the newly pro-
posed model to previously approved models. Here, each model
has a maximum wait time of ∆ = 2 and each interim analysis is
represented by a square. A checkmark indicates that the null
hypothesis is rejected and an “X” indicates that the interim
analysis is not performed. The final interim analysis for fˆ2 is
not performed because its GST only compares fˆ2 to fˆ0 and
not the newly approved model fˆ1. Thus, fˆ2 has no chance of
being approved.
sequence of hypothesis tests run, and a procedure that selects
the levels to perform the hypothesis tests. To build up to
aACP-BAC, we i) first describe a simple aACP skeleton that
launches a fixed sequence of group sequential tests (GSTs), ii)
add gate-keeping to increase its flexibility, and iii) finally pair
it with a sequence of F˜t-measurable functions {αt ∶ t = 1,2, ...}
for choosing the hypothesis test levels. The full algorithm is
given in Algorithm 1 in the Appendix. For now, we assume
the distributions are constant and simply use the notation →
in place of →,t. We discuss robustness to time trends in a
later section.
Let us first consider the a simple aACP skeleton that
compares each proposed model to previously approved models
using a single hypothesis test (Figure 3). More specifically, at
time t, it launches a group sequential -acceptability test with
the null hypothesis
H0 ∶ ∃t′ = 1, ..., t s.t. fˆAˆt′ ↛ fˆt. (1)
The number of interim analyses is the maximum wait time
∆t and the critical values are chosen according to an alpha-
spending function specified prior to launch (DeMets and
Lan, 1994). At each time point, we also perform interim
analyses for all active hypothesis tests (i.e. those not past
their maximum wait time). The aACP approves fˆj at time
t if it demonstrates acceptability to fˆAˆ1 , ..., fˆAˆt−1 . If multiple
models are acceptable, it selects the latest one.
A drawback of this simple aACP skeleton is that it fails
to adapt to new model approvals that occur in the middle of
a group sequential test (GST). Consider the example in Fig-
ure 3, where a GST with null hypothesis H0
fˆ0↛fˆ1 is launched
at time t = 1 and a second GST with null hypothesis H0
fˆ0↛fˆ2
is launched at time t = 2. If fˆ1 is approved at time t = 3, this
aACP cannot approve fˆ2 since its GST only compares fˆ2 to
fˆ0. Ideally, it could adapt to the new approval and add a test
comparing fˆ2 to fˆ1.
aACP-BAC addresses this issue by evaluating proposed
model fˆt using a family of acceptability tests instead (Fig-
ure 3). In addition to the aforementioned test for the null
6hypothesis (1), this family includes acceptability tests to test
each of the null hypotheses
H0,j ∶ fˆj ↛ fˆt for j = Aˆt + 1, ..., t − 1. (2)
As before, a model is approved at time t only if it demon-
strates acceptability compared to all approved models up to
time t. To control the online error rate, aACP-BAC controls
the FWER for each family of tests using a serial gate-keeping
procedure. Recall that gate-keeping tests hypotheses in a pre-
specified order and stops once it fails to reject a null hypothe-
sis (Dmitrienko and Tamhane, 2007). No alpha adjustment is
needed in gate-keeping; It controls FWER at α by performing
all tests at level α. Here, the tests are naturally ordered by the
index of the reference models, from oldest to latest. Moreover,
this ordering maximizes the probability of approval, assuming
the proposed models improve in predictive accuracy. Details
for performing GSTs with gate-keeping are given in Tamhane
et al. (2018).
To uniformly control BACW (⋅) at α, aACP-BAC computes
an over-estimate of BACW (t) at each time t and selects level
αˆt such that the over-estimate is bounded by α. Using a union
bound like that in Bonferroni correction, it uses the over-
estimate
B̂ACW (t) = t∑
t′=1 αˆt′1{t −W ≤ t′ +∆t′ ≤ t} (3)
and selects αˆt such that
B̂ACW (t) ≤ α. (4)
In the Appendix, we prove that aACP-BAC achieves the
nominal rate.
Alternatively, we can think of aACP-BAC as an alpha-
investing procedure (Foster and Stine, 2008) that begins with
an alpha-wealth of α, spends it when a family of tests is
launched, and earns it back when the family leaves the current
window. From this, we can see that choosing an infinitely
long window (W =∞) has low power because the aACP will
spend but never earn alpha-wealth. This is analogous to the
so-called “alpha-death” issue that occurs in procedures that
control online FWER (Ramdas et al., 2017). We sidestep the
issue of alpha-death by selecting a reasonable value for W .
4.2 Bad approval and benchmark ratios
If the goal is to ensure that the SaMD improves on average
and occasional drops in performance are tolerated, the ap-
proval policies for controlling BACW can be overly strict and
unnecessarily conservative. There are two solutions to this
problem. One approach (reward-approach) is to reward the
company for each superior model by resetting the level alpha.
The FDA essentially uses this procedure right now, as each
clinical trial resets the alpha-spending clock. Another idea
(FDR-approach) is to draw on the false discovery rate (FDR)
literature: These procedures control the expected proportion
of false rejections rather than the FWER, which has higher
power when some of the null hypotheses are false (Benjamini
and Hochberg, 1995). This section defines a second online
error rate based on these ideas.
In line with the reward-approach, we consider aACPs that
utilize approval and “benchmark” functions to label models.
Whereas an approved model should be acceptable to previous
̂A2 = 0 ̂A3 = 1 ̂A4 = 2
H 0̂
f0↛ϵ ̂f1
H 0̂
f0↛ϵ ̂f2
̂A1 = 0
Time 1                        2                          3                          4                         
H 0̂
f1↛ϵ ̂f2
H 0̂
f2↛ϵ ̂f3
H 0̂
f1↛ϵ ̂f3 ̂f0↛ϵ ̂f3OR
Figure 4. At each time point, this aACP launches a family
of group sequential tests (shaded gray boxes) comparing the
newly proposed model to previously approved models as well
as other models that might be approved in the interim. Within
each family, we test the hypotheses using a gatekeeping proce-
dure, which provides a mechanism for comparing a candidate
model to newly approved models in the interim. We use
the same notation in Figure 3. An arrow between squares
indicates that we rejected a null hypothesis and proceeded to
the next test in the gatekeeping sequence.
approvals, a benchmark model should 1) be a previously-
approved model and 2) be superior to the previous bench-
mark. A benchmark function Bt is formally defined as a
F˜t measurable function that outputs the index of the latest
benchmark model at time t. For t = 0, we have B0 ≡ 0. Again,
we use the hat notation to indicate the realized benchmark
index. A bad benchmark is one in which fˆBˆt−1 ↛0,t fˆBˆt . We
do not compare against all previous benchmarks since ↛0,t is
a transitive property when the superiority graph is constant.
Based on the FDR-approach, we now introduce bad ap-
proval and benchmark ratios. An aACP needs to control
both ratios to control the frequency of bad approvals and
benchmarks.
Definition 3: For NI margin , the bad approval ratio
within W -window at time T is
BARW (T ) = ∑Tt=1∨(T−W ) 1{∃t′ = 1, ..., t − 1 s.t. fˆAˆt′ ↛,t fˆAˆt}
1 +∑Tt=1∨(T−W ) 1{Bˆt ≠ Bˆt−1} .
(5)
The bad benchmark ratio within W -window at time T is
BBRW (T ) = ∑Tt=1∨(T−W ) 1{fˆBˆt−1 ↛0,t fˆBˆt}
1 +∑Tt=1∨(T−W ) 1{Bˆt ≠ Bˆt−1} . (6)
Since only approved models can be designated as benchmarks,
BARW is an upper bound for the proportion of bad approvals
(this is approximate because the denominator is off by one).
So if a modification always decreases or increases performance
by a single unit, BARW (⋅) < 0.5 means that the currently
approved model is no worse than the initial version.
The denominator in (5) was deliberately chosen to be the
number of unique benchmarks rather than the number of
approvals because the latter is easy to inflate artificially.
We can simply propose models by alternating between two
models that are -acceptable to each other. This strategy does
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not work for benchmarks because they require demonstrating
superiority.
4.2.1 aACP to control bad approval and benchmark ratios.
Instead of controlling the expectations of (5) and (6), we
describe aACP-BABR for controlling the modified expected
bad approval and benchmark ratios. These modified ratios
are based on a similar quantity in the online FDR literature
known as modified online FDR (Foster and Stine, 2008). We
chose to control the modified versions because they can be
controlled under less restrictive conditions and using rela-
tively intuitive techniques (Ramdas et al., 2017). Moreover,
Foster and Stine (2008) found that modified online FDR
has similar long-running behavior to online FDR. We define
modified expected bad approval and benchmark ratios below.
Definition 4: For NI margin , the modified expected bad
approval ratio within W -window at time T is
meBARW (T )
= E [∑Tt=1∨(T−W ) 1{∃t′ = 1, ..., t − 1 s.t. fˆAˆt′ ↛,t fˆAˆt}]
E [1 +∑Tt=1∨(T−W ) 1{Bˆt ≠ Bˆt−1}] .
(7)
The modified expected bad benchmark ratio within W -
window at time T is
meBBRW (T ) = E [∑Tt=1∨(T−W ) 1{fˆBˆt−1 ↛0,t fˆBˆt}]
E [1 +∑Tt=1∨(T−W ) 1{Bˆt ≠ Bˆt−1}] . (8)
Next, we describe how aACP-BABR uniformly controls
meBARW (⋅) and meBBRW (⋅) at levels α and α′, respectively
(Algorithm 2). We begin with its skeleton and then discuss the
alpha-investing procedure. Again, we assume the distributions
Pt are constant.
aACP-BABR uses the acceptability tests from aACP-BAC
to approve modifications and superiority tests to discover
benchmarks. So at time t, in addition to launching a family of
acceptability tests to evaluate model fˆt for approval, aACP-
BABR also launches a family of group-sequential superiority
tests comparing fˆt to models with indices {Bˆt−1, ...., t − 1},
which are executed in a gate-keeping fashion from oldest to
latest. Let ∆′t be the maximum wait time for the superi-
ority tests, which can differ from the maximum wait time
for acceptability tests. A model fˆj is designated as a new
benchmark at time t if it demonstrates superiority to models
fˆBˆj−1 , ..., fˆBˆt−1 . If multiple benchmarks are discovered at the
same time, the aACP can choose any of them (we choose the
oldest one in our implementation).
aACP-BABR uses an alpha-investing procedure based on
Ramdas et al. (2017) to control the error rates. Let the F˜t-
measurable function α′t specify the level to perform supe-
riority tests launched at time t. At time t, aACP-BABR
constructs over-estimates of the error rates BARW (t) and
BBRW (t) and selects αˆt and αˆt′ such that the over-estimates
are no larger than the nominal levels. The over-estimates are
B̂ARW (t) = ∑tt′=1 αˆt′1{t −W ≤ t′ +∆t′ ≤ t}
1 +∑tt′=1∨(t−W ) 1{Bˆt′ ≠ Bˆt′−1} (9)
B̂BRW (t) = ∑tt′=1 αˆ′t′1{t −W ≤ t′ +∆′t′ ≤ t}
1 +∑tt′=1∨(t−W ) 1{Bˆt′ ≠ Bˆt′−1} . (10)
It selects αˆt and αˆ
′
t such that
B̂ARj(t) ≤ α ∀j = 1, ...,W (11)
B̂BRj(t) ≤ α′ ∀j = 1, ...,W. (12)
(We consider all window sizes since we also need to over-
estimate future errors BARW (t′) and BBRW (t′) for t′ > t.)
So, aACP-BABR earns alpha-wealth when new benchmarks
are discovered, which unites ideas from FDR-approach and
reward-approach. We prove in the Appendix that aACP-
BABR provides the desired error control.
4.3 Effect of time trends
Time trends are likely to occur when an aACP is run for a long
time. We now discuss how robust aACP-BAC and -BABR
are to time trends. We consider levels of increasing severity:
the distributions are relatively constant over time (no-trend),
the distributions are variable but the acceptability graphs
are relatively constant (graph-constant), and the acceptability
graphs change frequently (graph-changing).
When the distributions are relatively constant over time,
aACP-BAC and -BABR should approximately achieve their
nominal error rates. Recall that the two aACPs perform
paired T-tests by approximating the distribution Pt∶t+D−1 with
monitoring data sampled from Pj∨j′ ∶t−1, which is reasonable
when the distributions are relatively constant over time.
When there are multiple endpoints, one can either choose a
GST that rejects the null hypothesis when all endpoints sur-
pass the significance threshold at the same interim time point
or when the endpoints surpass their respective thresholds at
any interim timepoint. The former approach is more robust to
time trends with only modest differences in power (Asakura
et al., 2014).
When the distributions are not constant but the acceptabil-
ity graphs are, the GSTs have inflated error rates since they
only guarantee Type I error control under the strong null.
To handle heterogeneity in distributions over time, we can
instead use combination tests, such as Fisher’s product test
and the inverse normal combination test, to aggregate results
across time points (Fisher, 1932; Hedges and Olkin, 1985).
Since we assumed that the acceptability graphs are constant,
this tests the null hypothesis that the shared acceptability
graph does not have a particular edge (i.e. H0 ∶ f ↛,⋅ f ′); The
alternative hypothesis is that the edge exists. Thus, we can
replace GSTs with combination tests to achieve the desired
error control.
The most severe time trend is where the acceptability
graphs change frequently. Controlling error rates in this
setting is extremely difficult because previous data is not
informative for future time points. In fact, even defining an
error is difficult in this regime since the relative performance
of models is highly variable over time, e.g. an approval at
time t that looks bad at time t+1 might turn out to be a very
good at time t+ 2. As such, we recommend checking that the
acceptability graphs reasonably constant before using aACP-
BAC and -BABR.
85. Efficiency of an aACP
Just as hypothesis tests are judged by their Type I error
and power, an aACP should be judged by both the rate of
approving bad modifications and that for good modifications.
Using a decision-theoretic approach, we characterize the rate
of good approvals by the cumulative mean of an endpoint,
which we refer to as the cumulative utility. This quantity is
similar to “regret” in the online learning literature (Shalev-
Shwartz, 2012).
Definition 5: The cumulative utility of an aACP with
respect to endpoint m is
E [ 1
T
T∑
t=1m (fˆAˆt ,Pt)] . (13)
It is not possible to design a single aACP that maximizes (13)
for all possible model developers since we allow arbitrary un-
blinded adaptations. Instead, we will evaluate the cumulative
utility through a variety of simulation settings.
6. Simulations
Through simulation studies, we evaluate the operating char-
acteristics of the following aACPs:
(1) Blind: Approve all model updates
(2) Reset: Perform an acceptability test at level 0.05 against
the last-approved model
(3) Baseline: Perform an acceptability test at level 0.05
against the initial model
(4) aACP-BAC at level α = 0.2 with window W = 15
(5) aACP-BABR at level α = α′ = 0.2 with window W = 15.
The ratio of maximum wait times between the benchmark
and approval was fixed at ∆′/∆ = 2.
(6) Fixed: Only approve the first model
The first three aACPs have no error rate guarantees but
are policies one may consider; The others provide error rate
control. In the first two simulations, we try to inflate the
error rates of the aACPs. The next two study the cumulative
utility of the aACPs when proposed models are improving
on average. The last simulation explores the effects of time
trends.
All simulations below consider a binary classification task
where the endpoints are sensitivity and specificity. We test for
acceptability/superiority using repeated confidence intervals
(Cook, 1994) and Pocock alpha-spending functions (Pocock,
1977), where  = 0.05 for both endpoints. To compare the
aACPs in different scenarios, we plot endpoints of the ap-
proved models over time and show error rates in Table 1. Full
simulation details are in the Appendix.
6.1 Incremental model deterioration
In this simulation, the proposed models deteriorate gradually.
This can occur in practice for a number of reasons. For
instance, a manufacturer might try to make their SaMD sim-
pler, cheaper, and/or more interpretable by using fewer input
variables, collecting measurements through other means, or
training a less complex model. Even if their modifications are
well-intended, the sponsor might end up submitting inferior
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Figure 5. Comparison of the sensitivity and specificity
of models approved by different aACPs when the proposed
models are gradually deteriorating. (We omit aACP-Blind
from this plot since it would obviously perform the worst.)
models. A model developer can also inadvertently propose
adverse modifications if they repeatedly overfit to the training
data. Finally, a properly trained model can be inferior if the
training data is not representative of future time points if,
say, the biomarkers lose their prognostic value over time.
This simulation setup tries to induce bio-creep by submit-
ting models that are acceptable to the currently approved
model but gradually deteriorate over time. Each proposed
model is worse by /2 in one endpoint and better by /4 in
the other. By alternating between deteriorating the two end-
points, the manufacturer eventually submits strictly inferior
models.
Bio-creep occurs consistently when using the aACP-Reset
since it only compares against the most recently approved
model (Figure 5). Both the sensitivity and specificity for the
approved model at the final time point are significantly worse
than the initial model. aACP-BAC and aACP-BABR prop-
erly controlled the occurence of bio-creep since they require
modifications to demonstrate acceptability with respect to all
previously approved models.
6.2 Periodic model deterioration and improvement
Next we consider a simulation in which the proposed mod-
ifications periodically decline and improve in performance.
This scenario is more realistic than the previous section since
a manufacturer is unlikely to only submit bad modifications.
More specifically, the proposed models monotonically improve
in performance over the first fifteen time points and, there-
after, alternate between deteriorating and improving mono-
tonically every ten time points.
As expected, aACP-Baseline had the worst error and cu-
mulative utility. It performed like aACP-Blind and the perfor-
mances of the approved models were highly variable over time
(Figure 6). In contrast, the other aACPs displayed much less
variability and the performances were generally monotonically
increasing. aACP-Reset had the highest utility here because it
performs hypothesis tests at a higher level alpha than aACP-
BAC and aACP-BABR.
6.3 Accumulating data model updates
We now suppose the manufacturer automatically generates
modifications by training the same model on accumulating
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Figure 6. Comparison of the sensitivity and specificity
of models approved by different aACPs when the proposed
models periodically deteriorate and improve in performance.
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Figure 7. Comparison of the sensitivity and specificity
of models approved by different aACPs when the model
developer trains a logistic model on accumulating monitoring
data.
monitoring data. In this simulation, the developer iteratively
performs penalized logistic regression. Since model param-
eters are estimated with increasing precision, the expected
improvement decreases over time and performance eventually
plateaus. As such, we investigate aACP behavior over a
shorter time period.
aACP-Blind approved good modifications the fastest; The
remaining aACPs, excluding aACP-fixed, are close in cumu-
lative utility (Figure 7). The similarity in performance is be-
cause less efficient aACPs can “catch up” in this setup: Even
if an aACP has low power for detecting small improvements,
the model developer will eventually propose a modification
with a sufficiently large improvement that is easy to discern.
We note that aACP-BAC and -BABR behaved similarly in
this simulation because models improved at a slow pace
and performance plateaued over time. As such, aACP-BABR
often discovered one or no new benchmarks within a window
and was unable to earn alpha-wealth much of the time.
6.4 Significant model improvements
Next, we simulate a manufacturer that proposes models with
large improvements in performance at each time point. Large
improvements usually occur when the modifications signifi-
cantly change the model, such as adding a highly informative
biomarker or replacing a simple linear model with a complex
one that accounts for non-linearities and interactions.
Since large improvements are relatively rare, we used a
short total time. We designed the simulation to be less fa-
vorable for aACP-BAC and -BABR. The model developer
proposes a modification that improves both endpoints by 4%
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Figure 8. Comparison of the sensitivity and specificity of
models approved by different aACPs when the model devel-
oper adaptively proposes a significantly better model than
the currently approved model. We evaluate three different
settings for aACP-BABR, where a larger index means that
alpha-wealth is spent more greedily.
compared to the most recently approved model. Therefore an
aACP cannot catch up by simply waiting for large improve-
ments.
As expected, Blind-aACP is the most efficient, followed
by aACP-Baseline and aACP-Reset (Figure 8). The aACPs
with error rate control are less efficient. For example, the
performance of the final models approved by aACP-BABR
and aACP-Reset differed by 4% on average. Unlike in previous
simulations, there is a clear difference between using aACP-
BABR over aACP-BAP. Since the models here improve at a
fast pace, aACP-BABR earns enough alpha-wealth to discover
new benchmarks with high probability.
6.5 Robustness to time trends
Finally, we evaluate the robustness of aACP-BAC and -BABR
to time trends by simulating the three time trend severity
levels from Section 4.3. We simulate the endpoints of the
proposed models to follow a sinusoidal curve. In addition,
the proposed model is always strictly inferior to the currently
approved model on average. For the graph-constant setting,
the sinusoids are aligned so that the proposed model is un-
acceptable at all time points. For the graph-changing setting,
the sinusoids are offset by exactly half the period so that the
proposed model is superior to the currently approved model
at certain time points.
The error rates in the graph-constant and no-trend settings
were similar (Table 1), which implies that aACP-BAC and
-BABR still control error rates if the acceptability graphs
stay relatively constant. However, they performed poorly in
the graph-changing setting since bad modifications appeared
superior at particular time points.
7. Discussion
In this work, we have presented and evaluated different poli-
cies for regulating modifications to AI/ML-based SaMDs.
One of our motivations was to investigate the possibility
of bio-creep, due to the parallels between this problem and
noninferiority testing of new drugs. We found that the risk of
bio-creep is heightened in this regulatory problem compared
to the traditional drug development setting because software
modifications are easy and fast to deploy. Nonetheless, we
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show that aACPs with appropriate online error-rate guaran-
tees can sufficiently reduce the possibility of bio-creep without
substantial sacrifices in our ability to approve beneficial mod-
ifications, at least in the specific settings discussed in this
paper.
This paper only considers a limited scope of problems and
there are still many interesting directions for future work.
One direction is to develop more efficient aACPs, perhaps by
spending alpha-wealth more judiciously, discovering bench-
marks using a different procedure, sequestering monitoring
data for repeated testing, or considering the special case
with pre-specified modifications. Also, we have not considered
aACPs that regulate modifications to SaMDs that are in-
tended to treat and are evaluated based on patient outcomes.
Our results raise the interesting question regarding the gen-
eral structure of the regulatory policy framework. Although
aACP-BAC and -BABR mitigate the effect of bio-creep, they
cannot provide indefinite error rate control without large
sacrifices in cumulative utility. So if one desires both indefinite
error rate control and fast approval of good modifications,
perhaps the solution is not to use a fully automated approach.
For example, human experts could perform comprehensive
analyses every couple of years and the manufacturer could
use an aACP in between to quickly deploy modifications.
Finally, we highlight that regulating modifications to
AI/ML-based SaMDs is a highly complex problem. This paper
has primarily focused on the idealized setting of a constant
diagnostic environment. Our findings suggest that problems
with bio-creep is more pervasive when modifications are de-
signed to accommodate time trends in the patient population,
available measurements, and bioclinical practice. It is crucial
that we thoroughly understand the safety risks before allowing
modifications in these more complex settings.
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Appendix
Proofs
Theorem 1: aACP-BAC achieves uniform control of
BACW (⋅) at level α, i.e.
BACW (T ) ≤ α T = 1,2, ... (A.1)
Proof. At each time point, aACP-BAC launches a set of
hypothesis tests comparing fˆt to models with indices Mˆt ={Aˆ1, ..., Aˆt, Aˆt + 1, ..., t − 1}. Let the F˜t-measurable random
variable Gt indicate the indices of the true null hypotheses,
i.e.
Gˆt = {j ∈ Mˆt ∶ fˆj ↛ fˆt} .
It is easy to see that the number of bad approvals is upper
bounded by the number of incorrect rejections of the launched
null hypotheses, i.e.
T∑
1∨(T−W )1{∃t′ = 1,⋯, t − 1 s.t. fˆAˆt′ ↛ fˆAˆt}
≤ T∑
1∨(T−W )1{∃j ∈ Gˆt,∃t′ = 1,⋯,∆t, s.t. reject fˆj ↛ fˆt at time t + t′} .
(A.2)
Taking the expectations on both sides, BACW (T ) is upper-
bounded by
T∑
1∨(T−W )Pr (∃j ∈ Gˆt,∃t′ = 1,⋯,∆t, s.t. reject fˆj ↛ fˆt at time t + t′) .
(A.3)
Since the hypothesis tests are tested using a gatekeeping
procedure, each probability in (A.3) is equal to the probability
of rejecting the first true null hypothesis in the gatekeeping
sequence. Thus,
Pr (∃j ∈ Gˆt,∃t′ = 1,⋯,∆t, s.t. reject fˆj ↛ fˆt at time t + t′)
(A.4)=Pr (Gˆt ≠ ∅,∃t′ = 1,⋯,∆t, s.t. reject fˆmin Gˆt ↛ fˆt at time t + t′)
(A.5)≤E [Pr (Gˆt ≠ ∅,∃t′ = 1,⋯,∆t, s.t. reject fˆmin Gˆt ↛ fˆt at time t + t′ ∣ F˜t)]
(A.6)≤E [αˆt1{Gˆt ≠ ∅}] . (A.7)
Summing together the probabilities within the window, we
have
BACW (T ) ≤ E ⎡⎢⎢⎢⎢⎣
T∑
1∨(T−W ) αˆt
⎤⎥⎥⎥⎥⎦ ≤ α, (A.8)
where the last inequality follows from the fact that αˆt is
always selected such that
T∑
1∨(T−W ) αˆt ≤ α.
Theorem 2: aACP-BABR achieves uniform control of
meBARW (⋅) and meBBRW (⋅) at levels α and α′, respectively,
i.e.
meBARW (T ) ≤ α ∀T = 1,2,⋯ (A.9)
meBBRW (T ) ≤ α′ ∀T = 1,2,⋯ (A.10)
Proof. For all T , αˆT is selected such that
ˆBARW ′(T ) = ∑Tt=1 αˆt1{t −W ≤ t′ +∆t′ ≤ t}
1 +∑T−1t=1∨(T−W ′) 1{Bˆt−1 ≠ Bˆt} ≤ α ∀W ′ = 1, ...,W.
(A.11)
Note that we can always set αˆT = 0 to satisfy these con-
straints, assuming that (11) was satisfied at times t = 1, ..., T −
1. Using the result in the proof of Theorem 1, we then bound
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the numerator of BARW (T ) as follows
E
⎡⎢⎢⎢⎢⎣
T∑
t=1∨(T−W )1{∃t′ = 1, ..., t − 1 s.t. fˆAˆt′ ↛,t fˆAˆt}
⎤⎥⎥⎥⎥⎦ (A.12)
≤ E [ T∑
t=1 αˆt1{t −W ≤ t′ +∆t′ ≤ t}] (A.13)
≤ E ⎡⎢⎢⎢⎢⎣α
⎛⎝1 + T∑t=1∨(T−W )1{Bˆt−1 ≠ Bˆt}⎞⎠
⎤⎥⎥⎥⎥⎦ , (A.14)
where the last line follows from (A.11). Rearranging, we get
that meBARW (T ) ≤ α. The proof for uniform control of
meBBRW (⋅) is essentially the same, where we replace the
alpha-spending function with α′t and the threshold with α′.
Simulation settings
We ran 50 replicates for each simulation.
Incremental deterioration. We set total time T = 200 and
the maximum wait time ∆ = 5 for all models. The number of
new monitoring observations at each time point increments
by ten to estimate the true performance difference with in-
creasing precision over time, starting with 200 observations.
Periodic model deterioration and improvement. We set
total time T = 100 and maximum wait time ∆ = 5 for all
models. We accumulate 200 new observations at each time
point.
Accumulating data. Each patient is represented by 30
covariates and the true outcome is generated using a logistic
model. The developer performs logistic regression with a
lasso penalty and tunes the penalty parameter using cross-
validation. To increase the margin of model improvement at
later time points and the ability to detect small improvements,
we increase the number of training observations at each time
point by five, starting with size 20, and use a larger wait
time of ∆ = 10. The total time is T = 40 since the model
performance plateaus quickly.
Significant model improvements. In order to make the
model improvements significant with high probability, we
accumulate 650 observations at each time point, which is more
than the other simulation settings. Since large improvements
are relatively rare, we used a short total time of T = 20. Since
a company is likely more confident in these improvements, the
maximum wait time is set to ∆ = 3.
Time trends. The total time is T = 100 and the wait time
is ∆ = 5. We accumulate 300 new observations at each time
point.
Algorithm 1: aACP-BAC
for t = 1,2, ... do
Aˆt = Aˆt−1;
/* Determine if there are new approvals */
for j = Aˆt−1 + 1, ..., t − 1 do
if t ≤ j +∆j ; // If fˆj is under
consideration for approval
then
Run -acceptability tests: Test null
hypotheses fˆj′ ↛ fˆj for
j′ = Aˆ1, ..., Aˆj−1, Aˆj−1 + 1, ..., Aˆt−1 with
critical value cj(t) in gatekeeping style;
if All -acceptability tests pass then
Aˆt = j;
end
end
end
/* Launch new hypothesis tests for new model
proposal */
Launch family of -acceptability tests with null
hypotheses fˆj ↛ fˆt for j = Aˆ1, ...Aˆt, Aˆt + 1, ..., t − 1;
Choose αˆt such that (4) is satisfied;
Select alpha-spending function for αˆt and its critical
value function ct(⋅) over the next ∆t time points.;
end
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Algorithm 2: aACP-BABR
for t = 1,2, ... do
Aˆt = Aˆt−1;
/* Determine if there are new approvals */
for j = Aˆt−1 + 1, ..., t − 1 do
if t ≤ j +∆j ; // If fˆj is under
consideration for approval
then
Run -acceptability tests: Test null
hypotheses fˆj′ ↛ fˆj for j′ = Aˆj , ..., Aˆt−1 with
critical value cj(t) in gatekeeping style;
if All -acceptability tests pass then
Aˆt = j;
end
end
end
Bˆt = Bˆt−1;
/* Determine if there are new benchmarks */
for j = Aˆ1, ..., Aˆt−1 do
if j > Bˆt−1 and t ≤ j +∆j ; // If fˆj is under
consideration for approval
then
Run superiority tests: Test null hypotheses
fˆj′ ↛0 fˆj for j′ = Bˆj , ..., Bˆt−1 with critical
value c′j(t) in gatekeeping style;
if All superiority tests pass then
Aˆt = j;
end
end
end
/* Launch new hypothesis tests for new model
proposal */
Launch family of -acceptability tests with null
hypotheses fˆj ↛ fˆt for j = Aˆ1, ...Aˆt, Aˆt + 1, ..., t − 1;
Launch family of superiority tests with null
hypotheses fˆj ↛ fˆt for j = Bˆt, ..., t − 1;
Choose αˆt, αˆ
′
t such that (11) and (12) are satisfied;
Select alpha-spending function for αˆt and αˆ
′
t and
their critical value functions ct(⋅), c′t(⋅) over the next
∆t time points.;
end
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Final Cumulative utility
approver BACW # approved Specificity Sensitivity Specificity Sensitivity meBARW meBBRW
Incremental model deterioration, Section 6.1
BABR 0.000 1.940 0.782 0.777 0.784 0.784 0.000 0.000
BAC 0.000 1.960 0.781 0.778 0.783 0.784 0.000 0.000
Baseline 0.060 2.220 0.778 0.779 0.781 0.781 0.060 0.000
Fixed 0.000 1.000 0.787 0.788 0.787 0.788 0.000 0.000
Reset 1.180 9.860 0.719 0.715 0.763 0.761 0.541 0.541
Periodic model deterioration/improvement, Section 6.2
BABR 0.000 2.920 0.799 0.799 0.786 0.787 0.000 0.000
BAC 0.000 2.940 0.799 0.799 0.786 0.787 0.000 0.000
Baseline 6.300 43.360 0.749 0.749 0.765 0.766 6.300 0.000
Blind 15.000 99.000 0.712 0.711 0.762 0.762 15.000 0.000
Fixed 0.000 1.000 0.697 0.697 0.697 0.697 0.000 0.000
Reset 0.020 3.740 0.801 0.801 0.790 0.791 0.020 0.020
Training on accumulating data, Section 6.3
BABR 0.040 3.460 0.955 0.954 0.858 0.825 0.025 0.000
BAC 0.020 3.240 0.954 0.952 0.858 0.825 0.020 0.000
Baseline 0.100 22.120 0.958 0.958 0.884 0.845 0.100 0.000
Blind 3.840 39.000 0.958 0.958 0.928 0.922 3.840 0.000
Fixed 0.000 1.000 0.688 0.574 0.688 0.574 0.000 0.000
Reset 0.080 4.520 0.956 0.956 0.879 0.840 0.028 0.168
Significant model improvement, Section 6.4
BABR 0.000 4.020 0.802 0.802 0.757 0.757 0.000 0.000
BAC 0.000 3.980 0.801 0.801 0.753 0.753 0.000 0.000
Baseline 0.000 17.160 0.803 0.803 0.778 0.779 0.000 0.000
Blind 0.000 19.000 0.803 0.803 0.790 0.790 0.000 0.000
Fixed 0.000 1.000 0.681 0.682 0.682 0.682 0.000 0.000
Reset 0.000 4.420 0.802 0.802 0.770 0.771 0.000 0.007
Time trend experiment, Section 6.5
no-trend-BAC 0.020 1.020 0.712 0.712 0.712 0.712 0.000 0.000
no-trend-Fixed 0.000 1.000 0.712 0.712 0.712 0.712 0.000 0.000
graph-constant-BAC 0.020 1.020 0.651 0.651 0.712 0.712 0.020 0.000
graph-constant-Fixed 0.000 1.000 0.651 0.652 0.712 0.712 0.000 0.000
graph-changing-BAC — 1.820 0.632 0.633 0.687 0.687 — —
graph-changing-Fixed — 1.000 0.772 0.773 0.711 0.712 — —
Table 1
Comparison of aACP in different simulation settings. Columns BACW ,meBARW ,meBBRW display the maximum error rate over all time points. In the
incremental model deterioration, we omit aACP-Blind since it always converges to completely uninformative classifier. In the time trend experiments, we omit
results from aACP-BABR because they are very similar to aACP-BAC.
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